Medicines for Malaria Venture

Medicines for Malaria Venture
Name	Medicines for Malaria Venture
Formation	1999
Type	Public–private partnership
Headquarters	Geneva
Location	Switzerland
Leader title	CEO
Leader name	Roger Perlmutter

Medicines for Malaria Venture is a public–private partnership founded in 1999 to develop antimalarial medicines, working across global health networks to advance drug discovery and access. It brings together pharmaceutical companies, philanthropic foundations, academic institutions, regulatory bodies, and multilateral organizations to address malaria through coordinated research, development, and delivery initiatives. The organization operates at the nexus of translational science, product development, and policy, engaging stakeholders from Geneva to Dakar and partnering with institutions in North America, Europe, Asia, and Africa.

History

The organization was established in 1999 with initial support from the Bill & Melinda Gates Foundation, the World Health Organization, and the World Bank as part of a broader late‑20th‑century effort following meetings such as the G8 summit discussions on global health. Early engagement included collaborators from GlaxoSmithKline, Novartis, Pfizer, and academic centers such as the University of Oxford and the University of Cambridge. Through the 2000s it expanded ties to research institutes like the Wellcome Trust Sanger Institute and the Institute Pasteur, and to regulatory partners including the European Medicines Agency and the US Food and Drug Administration. The organization’s timeline intersects with major initiatives like the creation of the Global Fund to Fight AIDS, Tuberculosis and Malaria and the launch of the Roll Back Malaria Partnership. Leadership and advisory roles have drawn from figures associated with Harvard University, Imperial College London, Johns Hopkins University, and the London School of Hygiene & Tropical Medicine.

Mission and Objectives

The stated mission aligns with priorities articulated by the United Nations and the World Health Assembly, aiming to reduce malaria morbidity and mortality through product development strategies similar to those used by pharmaceutical pioneers such as Paul Janssen and organizations like the Drugs for Neglected Diseases initiative. Objectives include accelerating discovery pipelines at research hubs like the Biotechnology Innovation Organization partners, supporting clinical trials in networks tied to the Kenya Medical Research Institute and the Institut Pasteur de Dakar, and ensuring regulatory approvals via pathways with the European Medicines Agency and the US Food and Drug Administration. The strategy emphasizes partnerships with funders such as the Wellcome Trust, engagement with policymakers from the African Union, and alignment with targets set by the Sustainable Development Goals and the World Health Organization Global Malaria Programme.

Research and Development Programs

Programmatic activity spans early discovery networks collaborating with chemical libraries from institutions like Novartis Institutes for BioMedical Research, phenotypic screening hubs modeled after efforts at the Broad Institute, and medicinal chemistry consortia including researchers from the Swiss Tropical and Public Health Institute and the Max Planck Society. Clinical development has used trial sites in collaboration with the Ifakara Health Institute, the Molecular Partners AG style biotech sector, and contract research organizations linked to CROs headquartered near Basel. Projects have targeted blood‑stage, liver‑stage, and transmission‑blocking candidates, leveraging assays developed at the National Institutes of Health, Pasteur Institute, Karolinska Institutet, and the University of California, San Francisco. The portfolio has included partnerships with companies such as AstraZeneca, Eli Lilly and Company, Bayer, and spin‑outs from Novartis and GSK.

Partnerships and Collaborations

Collaborators span philanthropic donors like the Gates Foundation and the Wellcome Trust, multilateral agencies including the World Health Organization and the Global Fund, academic institutions such as the University of Oxford, University of Cape Town, and Makerere University, and industry partners including Novartis, GlaxoSmithKline, Sanofi, and Pfizer. Regional disease control programs including the African Union's health initiatives and national ministries of health in Nigeria, Kenya, and Ghana have hosted implementation studies. Regulatory and policy links involve the European Medicines Agency, the US Food and Drug Administration, and the African Medicines Agency. Additional collaborations include networks like the Medicines for Neglected Diseases initiative, the Coalition for Epidemic Preparedness Innovations, and the Drugs for Neglected Diseases initiative.

Funding and Governance

Funding sources combine philanthropic contributions from the Bill & Melinda Gates Foundation and the Wellcome Trust, governmental support from entities such as UK Research and Innovation and the Swiss Agency for Development and Cooperation, and in‑kind partnerships with multinational firms like Novartis and GlaxoSmithKline. Governance structures draw on best practices from organizations including the World Health Organization and the Global Fund, with oversight involving experts affiliated with Harvard University, Imperial College London, Johns Hopkins University, and the London School of Hygiene & Tropical Medicine. The board and advisory councils have included representatives from the Pharmaceutical Research and Manufacturers of America, the European Federation of Pharmaceutical Industries and Associations, and national research councils such as the Medical Research Council (UK).

Impact and Notable Achievements

Achievements include progression of combination therapies into regulatory review with partners like Novartis and GlaxoSmithKline, advancement of novel chemical entities through clinical phases in collaboration with the National Institutes of Health and trial networks in Burkina Faso, Mali, and Tanzania, and contributions to policy guidance adopted by the World Health Organization. The organization’s work has informed implementation strategies used by the Global Fund to Fight AIDS, Tuberculosis and Malaria and national malaria control programs in Nigeria and Mozambique. Recognition and influence have intersected with awards and forums such as sessions at the World Economic Forum and publications in journals associated with Nature Publishing Group and The Lancet. Its collaborative model has been cited alongside efforts by the Wellcome Trust Sanger Institute and the Broad Institute as a template for public–private partnerships tackling infectious diseases.

Category:Non-profit organizations based in Switzerland